Related Experiment Video
Updated: Aug 7, 2026
08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
SPECT in dementia: clinical and pathological correlation
1Department of Psychiatry, VA Medical Center, West Los Angeles UCLA School of Medicine 90073, USA.
Journal of the American Geriatrics Society
|November 1, 1995
Summary
Single photon emission computed tomography (SPECT) improved dementia diagnosis accuracy to 92.6% compared to clinical diagnosis (74.1%). SPECT aids in differentiating Alzheimer's disease, Frontotemporal Dementia, and Jakob-Creutzfeldt Disease but not Parkinsonian Dementias from Alzheimer's disease.
Area of Science:
- Neurology
- Radiology
- Pathology
Background:
- Clinical diagnosis of dementia is often inaccurate, especially for non-Alzheimer's disease (AD) dementias and atypical AD cases.
- Single photon emission computed tomography (SPECT) is a functional imaging technique with potential for diagnosing neurodegenerative disorders.
- Few clinicopathological studies have validated the use of SPECT in dementia diagnosis.
Purpose of the Study:
- To evaluate the diagnostic accuracy of SPECT imaging in dementia patients.
- To compare SPECT findings with clinical and autopsy diagnoses.
- To identify distinct SPECT patterns associated with different types of dementia.
Main Methods:
- Twenty-seven consecutive dementia patients underwent clinical evaluation and SPECT imaging.
- SPECT findings were correlated with clinical diagnoses and autopsy results.
- Analysis focused on the accuracy of SPECT in predicting pathological diagnoses.
Main Results:
- SPECT accurately predicted the pathological diagnosis in 25 out of 27 patients (92.6%), surpassing clinical diagnosis accuracy (74.1%).
- Distinct SPECT patterns were observed for Alzheimer's disease (AD), Fronto-Temporal Dementia (FTD), and Jakob-Creutzfeldt Disease (JCD).
- SPECT identified vascular insults missed by CT and MRI, and revealed varied pathologies in Parkinsonian-Dementias (PD) with similar temporal-parietal patterns to AD.
Conclusions:
- SPECT imaging offers valuable diagnostic information for dementia, particularly in differentiating AD, FTD, and JCD.
- SPECT does not reliably distinguish Parkinsonian Dementias (PD) from Alzheimer's disease (AD).
- Further research may explore SPECT's role in refining differential diagnoses for complex dementia cases.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...